Bulk Manufacturer of Controlled Substances Application: S & B Pharma LLC DBA Norac Pharma

Primary source

Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.

Published

February 4, 2026

Issuing agencies

Justice DepartmentDrug Enforcement Administration

Abstract

S & B Pharma LLC DBA Norac Pharma has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

Full Text

<html>
<head>
<title>Federal Register, Volume 91 Issue 23 (Wednesday, February 4, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 23 (Wednesday, February 4, 2026)]
[Notices]
[Pages 5110-5111]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-02232]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-1658]


Bulk Manufacturer of Controlled Substances Application: S & B 
Pharma LLC DBA Norac Pharma

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

-----------------------------------------------------------------------

SUMMARY: S & B Pharma LLC DBA Norac Pharma has applied to be registered 
as a bulk manufacturer of basic class(es) of controlled substance(s). 
Refer to Supplementary Information listed below for further drug 
information.

DATES: Registered bulk manufacturers of the affected basic class(es), 
and applicants, therefore, may submit electronic comments on or 
objections to the issuance of the proposed registration on or before 
April 6, 2026. Such persons may also file a written request for a 
hearing on the application on or before April 6, 2026.

ADDRESSES: The Drug Enforcement Administration requires that all

[[Page 5111]]

comments be submitted electronically through the Federal eRulemaking 
Portal, which provides the ability to type short comments directly into 
the comment field on the web page or attach a file for lengthier 
comments. Please go to <a href="https://www.regulations.gov">https://www.regulations.gov</a> and follow the 
online instructions at that site for submitting comments. Upon 
submission of your comment, you will receive a Comment Tracking Number. 
Please be aware that submitted comments are not instantaneously 
available for public view on <a href="https://www.regulations.gov">https://www.regulations.gov</a>. If you have 
received a Comment Tracking Number, your comment has been successfully 
submitted and there is no need to resubmit the same comment.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this 
is notice that on January 13, 2026, S & B Pharma LLC DBA Norac Pharma, 
405 South Motor Avenue, Azusa, California 91702, applied to be 
registered as a bulk manufacturer of the following basic class(es) of 
controlled substance(s):

------------------------------------------------------------------------
                                           Drug
          Controlled substance             code          Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric Acid...............    2010  I
Marihuana...............................    7360  I
Tetrahydrocannabinols...................    7370  I
Amphetamine.............................    1100  II
Methamphetamine.........................    1105  II
Lisdexamfetamine........................    1205  II
Methylphenidate.........................    1724  II
Pentobarbital...........................    2270  II
4-Anilino-N-phenethyl-4-piperidine          8333  II
 (ANPP).
Tapentadol..............................    9780  II
Fentanyl................................    9801  II
------------------------------------------------------------------------

    The company plans to manufacture the above listed controlled 
substances for internal research and for development purposes as part 
of the process in seeking Food and Drug Administration approval prior 
to distribution to customers. No other activities for these drug codes 
are authorized for this registration.

Thomas Prevoznik,
Deputy Assistant Administrator.
[FR Doc. 2026-02232 Filed 2-3-26; 8:45 am]
BILLING CODE P


</pre></body>
</html>

View on FederalRegister.gov →Plain-text source

Indexed from Federal Register on February 4, 2026.

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.